Spero Therapeutics, Inc. financial data

Symbol
SPRO on Nasdaq
Industry
Pharmaceutical Preparations
Location
675 Massachusetts Avenue, 14 Th Floor, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Spero Therapeutics, LLC (to 3/21/2017)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 302 % -34.9%
Debt-to-equity 81.9 % +5.2%
Return On Assets -92.1 % -63.4%
Operating Margin -1.04 % +74.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.5M shares +2.87%
Common Stock, Shares, Outstanding 54.3M shares +2.48%
Entity Public Float 76M USD
Common Stock, Value, Issued 54K USD +1.89%
Weighted Average Number of Shares Outstanding, Basic 54.1M shares +2.68%
Weighted Average Number of Shares Outstanding, Diluted 54.1M shares +2.68%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 106M USD +37%
Revenue from Contract with Customer, Excluding Assessed Tax 542K USD -45.1%
Research and Development Expense 84.5M USD +69.1%
General and Administrative Expense 23.1M USD -9.9%
Operating Income (Loss) -1.1M USD +64.7%
Nonoperating Income (Expense) 4.71M USD +26.6%
Income Tax Expense (Benefit) -290K USD -113%
Net Income (Loss) Attributable to Parent -17.9M USD -50.4%
Earnings Per Share, Basic 0.08 USD/shares -81.8%
Earnings Per Share, Diluted 0.08 USD/shares -81.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 76.3M USD -18.7%
Marketable Securities, Current 0 USD -100%
Assets, Current 132M USD +28.8%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 3.38M USD -23.2%
Other Assets, Noncurrent 153K USD -64.7%
Assets 135M USD +26.2%
Accounts Payable, Current 6.09M USD +452%
Employee-related Liabilities, Current 3.28M USD +54.6%
Liabilities, Current 49.1M USD +92.8%
Operating Lease, Liability, Noncurrent 2.88M USD -30%
Liabilities 69.7M USD +30.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -439M USD +0.79%
Stockholders' Equity Attributable to Parent 65.5M USD +22%
Liabilities and Equity 135M USD +26.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 5.94M USD
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 54.3M shares +2.48%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 5.94M USD
Deferred Tax Assets, Valuation Allowance 108M USD -6.02%
Deferred Tax Assets, Gross 108M USD -6.02%
Operating Lease, Liability 5.54M USD -16.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 22.8M USD +91.2%
Lessee, Operating Lease, Liability, to be Paid 6.58M USD -20.4%
Property, Plant and Equipment, Gross 3.62M USD 0%
Operating Lease, Liability, Current 1.74M USD +1.64%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.72M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.69M USD +24.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.03M USD -36.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.75M USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 25.6M USD -67.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.96M USD 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 0 USD -100%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%